Site icon EngerLab

Publications

Show all

2020

Famulari, Gabriel; Alfieri, Joanne; Duclos, Marie; Vuong, Té; Enger, Shirin A.

Can intermediate-energy sources lead to elevated bone doses for prostate and head & neck high-dose-rate brachytherapy? Journal Article

In: Brachytherapy, vol. 19, no. 2, pp. 255–263, 2020, ISSN: 1873-1449.

Abstract | Links | BibTeX | Tags: Bone and Bones, Brachytherapy, Cobalt Radioisotopes, Computer Simulation, Computer-Assisted, Dose calculation, Gadolinium, Humans, Intermediate-energy source, Iridium Radioisotopes, Male, Monte Carlo, Prostatic Neoplasms, Radiation Dosage, Radioisotopes, Radiotherapy Dosage, Radiotherapy Planning, Selenium Radioisotopes, Tissue composition, Tongue Neoplasms, Ytterbium

@article{famulari_can_2020,
title = {Can intermediate-energy sources lead to elevated bone doses for prostate and head & neck high-dose-rate brachytherapy?},
author = {Gabriel Famulari and Joanne Alfieri and Marie Duclos and Té Vuong and Shirin A. Enger},
doi = {10.1016/j.brachy.2019.12.004},
issn = {1873-1449},
year = {2020},
date = {2020-04-01},
journal = {Brachytherapy},
volume = {19},
number = {2},
pages = {255--263},
abstract = {PURPOSE: Several radionuclides with high (60Co, 75Se) and intermediate (169Yb, 153Gd) energies have been investigated as alternatives to 192Ir for high-dose-rate brachytherapy. The purpose of this study was to evaluate the impact of tissue heterogeneities for these five high- to intermediate-energy sources in prostate and head & neck brachytherapy. METHODS AND MATERIALS: Treatment plans were generated for a cohort of prostate (n = 10) and oral tongue (n = 10) patients. Dose calculations were performed using RapidBrachyMCTPS, an in-house Geant4-based Monte Carlo treatment planning system. Treatment plans were simulated using 60Co, 192Ir, 75Se, 169Yb, and 153Gd as the active core of the microSelectron v2 source. Two dose calculation scenarios were presented: (1) dose to water in water (Dw,w), and (2) dose to medium in medium (Dm,m).
RESULTS: Dw,w overestimates planning target volume coverage compared with Dm,m, regardless of photon energy. The average planning target volume D90 reduction was ∼1% for high-energy sources, whereas larger differences were observed for intermediate-energy sources (1%-2% for prostate and 4%-7% for oral tongue). Dose differences were not clinically relevant (textless5%) for soft tissues in general. Going from Dw,w to Dm,m, bone doses were increased two- to three-fold for 169Yb and four- to five-fold for 153Gd, whereas the ratio was close to ∼1 for high-energy sources.
CONCLUSIONS: Dw,w underestimates the dose to bones and, to a lesser extent, overestimates the dose to soft tissues for radionuclides with average energies lower than 192Ir. Further studies regarding bone toxicities are needed before intermediate-energy sources can be adopted in cases where bones are in close vicinity to the tumor.},
keywords = {Bone and Bones, Brachytherapy, Cobalt Radioisotopes, Computer Simulation, Computer-Assisted, Dose calculation, Gadolinium, Humans, Intermediate-energy source, Iridium Radioisotopes, Male, Monte Carlo, Prostatic Neoplasms, Radiation Dosage, Radioisotopes, Radiotherapy Dosage, Radiotherapy Planning, Selenium Radioisotopes, Tissue composition, Tongue Neoplasms, Ytterbium},
pubstate = {published},
tppubtype = {article}
}

Close

PURPOSE: Several radionuclides with high (60Co, 75Se) and intermediate (169Yb, 153Gd) energies have been investigated as alternatives to 192Ir for high-dose-rate brachytherapy. The purpose of this study was to evaluate the impact of tissue heterogeneities for these five high- to intermediate-energy sources in prostate and head & neck brachytherapy. METHODS AND MATERIALS: Treatment plans were generated for a cohort of prostate (n = 10) and oral tongue (n = 10) patients. Dose calculations were performed using RapidBrachyMCTPS, an in-house Geant4-based Monte Carlo treatment planning system. Treatment plans were simulated using 60Co, 192Ir, 75Se, 169Yb, and 153Gd as the active core of the microSelectron v2 source. Two dose calculation scenarios were presented: (1) dose to water in water (Dw,w), and (2) dose to medium in medium (Dm,m).
RESULTS: Dw,w overestimates planning target volume coverage compared with Dm,m, regardless of photon energy. The average planning target volume D90 reduction was ∼1% for high-energy sources, whereas larger differences were observed for intermediate-energy sources (1%-2% for prostate and 4%-7% for oral tongue). Dose differences were not clinically relevant (textless5%) for soft tissues in general. Going from Dw,w to Dm,m, bone doses were increased two- to three-fold for 169Yb and four- to five-fold for 153Gd, whereas the ratio was close to ∼1 for high-energy sources.
CONCLUSIONS: Dw,w underestimates the dose to bones and, to a lesser extent, overestimates the dose to soft tissues for radionuclides with average energies lower than 192Ir. Further studies regarding bone toxicities are needed before intermediate-energy sources can be adopted in cases where bones are in close vicinity to the tumor.

Close

2018

Famulari, Gabriel; Pater, Piotr; Enger, Shirin A.

Microdosimetric Evaluation of Current and Alternative Brachytherapy Sources-A Geant4-DNA Simulation Study Journal Article

In: International Journal of Radiation Oncology, Biology, Physics, vol. 100, no. 1, pp. 270–277, 2018, ISSN: 1879-355X.

Abstract | Links | BibTeX | Tags: Brachytherapy, Gadolinium, Imaging, Iodine Radioisotopes, Iridium Radioisotopes, Linear Energy Transfer, Monte Carlo Method, Phantoms, Radioisotopes, Radiometry, Radiotherapy Dosage, Relative Biological Effectiveness, Selenium Radioisotopes, Ytterbium

@article{famulari_microdosimetric_2018,
title = {Microdosimetric Evaluation of Current and Alternative Brachytherapy Sources-A Geant4-DNA Simulation Study},
author = {Gabriel Famulari and Piotr Pater and Shirin A. Enger},
doi = {10.1016/j.ijrobp.2017.09.040},
issn = {1879-355X},
year = {2018},
date = {2018-01-01},
journal = {International Journal of Radiation Oncology, Biology, Physics},
volume = {100},
number = {1},
pages = {270--277},
abstract = {PURPOSE: Radioisotopes such as 75Se, 169Yb, and 153Gd have photon energy spectra and half-lives that make them excellent candidates as alternatives to 192Ir for high-dose-rate brachytherapy. The aim of the present study was to evaluate the relative biological effectiveness (RBE) of current (192Ir, 125I, 103Pd) and alternative (75Se, 169Yb, 153Gd) brachytherapy radionuclides using Monte Carlo simulations of lineal energy distributions.
METHODS AND MATERIALS: Brachytherapy sources (microSelectron v2 [192Ir, 75Se, 169Yb, 153Gd], SelectSeed [125I], and TheraSeed [103Pd]) were placed in the center of a spherical water phantom with a radius of 40 cm using the Geant4 Monte Carlo simulation toolkit. The kinetic energy of all primary, scattered, and fluorescence photons interacting in a scoring volume were tallied at various depths from the source. Electron tracks were generated by sampling the photon interaction spectrum and tracking all the interactions down to 10 eV using the event-by-event capabilities of the Geant4-DNA models. The dose mean lineal energy (y¯D) values were obtained through random sampling of transfer points and overlaying spherical scoring volumes within the associated volume of the tracks. The scoring volume diameter was determined by fitting the y¯D ratio for 125I to its observed RBE.
RESULTS: y¯D increased with the increasing distance from the source for 192Ir, 75Se, and 169Yb, remained constant for 153Gd and 125I, and decreased for 103Pd. The diameter at which the y¯D ratio coincided with the RBE of 1.15 to 1.20 for 125I was ∼25 to 40 nm. The RBE (reference 1 MeV photons) at high doses and dose rates for 192Ir, 75Se, 169Yb, 153Gd, 125I, and 103Pd was 1.028 to 1.034, 1.05 to 1.07, 1.12 to 1.15, 1.16 to 1.21, 1.15 to 1.20, and 1.17 to 1.22, respectively.
CONCLUSIONS: The radiation quality of the radionuclides under investigation was greater than that of high-energy photons. The present study has provided a set of values to modify the prescription doses for brachytherapy to account for the variation in radiation quality among radionuclides.},
keywords = {Brachytherapy, Gadolinium, Imaging, Iodine Radioisotopes, Iridium Radioisotopes, Linear Energy Transfer, Monte Carlo Method, Phantoms, Radioisotopes, Radiometry, Radiotherapy Dosage, Relative Biological Effectiveness, Selenium Radioisotopes, Ytterbium},
pubstate = {published},
tppubtype = {article}
}

Close

PURPOSE: Radioisotopes such as 75Se, 169Yb, and 153Gd have photon energy spectra and half-lives that make them excellent candidates as alternatives to 192Ir for high-dose-rate brachytherapy. The aim of the present study was to evaluate the relative biological effectiveness (RBE) of current (192Ir, 125I, 103Pd) and alternative (75Se, 169Yb, 153Gd) brachytherapy radionuclides using Monte Carlo simulations of lineal energy distributions.
METHODS AND MATERIALS: Brachytherapy sources (microSelectron v2 [192Ir, 75Se, 169Yb, 153Gd], SelectSeed [125I], and TheraSeed [103Pd]) were placed in the center of a spherical water phantom with a radius of 40 cm using the Geant4 Monte Carlo simulation toolkit. The kinetic energy of all primary, scattered, and fluorescence photons interacting in a scoring volume were tallied at various depths from the source. Electron tracks were generated by sampling the photon interaction spectrum and tracking all the interactions down to 10 eV using the event-by-event capabilities of the Geant4-DNA models. The dose mean lineal energy (y¯D) values were obtained through random sampling of transfer points and overlaying spherical scoring volumes within the associated volume of the tracks. The scoring volume diameter was determined by fitting the y¯D ratio for 125I to its observed RBE.
RESULTS: y¯D increased with the increasing distance from the source for 192Ir, 75Se, and 169Yb, remained constant for 153Gd and 125I, and decreased for 103Pd. The diameter at which the y¯D ratio coincided with the RBE of 1.15 to 1.20 for 125I was ∼25 to 40 nm. The RBE (reference 1 MeV photons) at high doses and dose rates for 192Ir, 75Se, 169Yb, 153Gd, 125I, and 103Pd was 1.028 to 1.034, 1.05 to 1.07, 1.12 to 1.15, 1.16 to 1.21, 1.15 to 1.20, and 1.17 to 1.22, respectively.
CONCLUSIONS: The radiation quality of the radionuclides under investigation was greater than that of high-energy photons. The present study has provided a set of values to modify the prescription doses for brachytherapy to account for the variation in radiation quality among radionuclides.

Close

2017

Famulari, Gabriel; Urlich, Tomas; Armstrong, Andrea; Enger, Shirin A.

Practical aspects of 153Gd as a radioactive source for use in brachytherapy Journal Article

In: Applied Radiation and Isotopes: Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine, vol. 130, pp. 131–139, 2017, ISSN: 1872-9800.

Abstract | Links | BibTeX | Tags: (153)Gd, Brachytherapy, Gadolinium, Humans, Neutron Capture Therapy, Nuclear Reactors, Radiochemical separation, Radioisotopes, Radionuclide production, Radiotherapy Dosage, Specific activity, Thermal neutron capture cross section

@article{famulari_practical_2017,
title = {Practical aspects of 153Gd as a radioactive source for use in brachytherapy},
author = {Gabriel Famulari and Tomas Urlich and Andrea Armstrong and Shirin A. Enger},
doi = {10.1016/j.apradiso.2017.09.028},
issn = {1872-9800},
year = {2017},
date = {2017-12-01},
journal = {Applied Radiation and Isotopes: Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine},
volume = {130},
pages = {131--139},
abstract = {The goal of this study was to investigate the production, purification and immobilization techniques for a 153Gd brachytherapy source. We have investigated the maximum attainable specific activity of 153Gd through the irradiation of Gd2O3 enriched to 30.6% 152Gd at McMaster Nuclear Reactor. The advantage of producing 153Gd through this production pathway is the possibility to irradiate pre-sealed pellets of 152Gd enriched Gd2O3, thereby removing the need to perform chemical separation with large quantities of radio-impurities. However, small amounts of long-lived impurities are produced from the irradiation of enriched 152Gd targets due to traces of Eu in the sample. If the amount of impurities produced is deemed unacceptable, 153Gd can be isolated as an aqueous solution, chemically separated from impurities and loaded onto a sorbent with a high affinity for Gd before encapsulation.},
keywords = {(153)Gd, Brachytherapy, Gadolinium, Humans, Neutron Capture Therapy, Nuclear Reactors, Radiochemical separation, Radioisotopes, Radionuclide production, Radiotherapy Dosage, Specific activity, Thermal neutron capture cross section},
pubstate = {published},
tppubtype = {article}
}

Close

The goal of this study was to investigate the production, purification and immobilization techniques for a 153Gd brachytherapy source. We have investigated the maximum attainable specific activity of 153Gd through the irradiation of Gd2O3 enriched to 30.6% 152Gd at McMaster Nuclear Reactor. The advantage of producing 153Gd through this production pathway is the possibility to irradiate pre-sealed pellets of 152Gd enriched Gd2O3, thereby removing the need to perform chemical separation with large quantities of radio-impurities. However, small amounts of long-lived impurities are produced from the irradiation of enriched 152Gd targets due to traces of Eu in the sample. If the amount of impurities produced is deemed unacceptable, 153Gd can be isolated as an aqueous solution, chemically separated from impurities and loaded onto a sorbent with a high affinity for Gd before encapsulation.

Close

2014

Adams, Quentin E.; Xu, Jinghzu; Breitbach, Elizabeth K.; Li, Xing; Enger, Shirin A.; Rockey, William R.; Kim, Yusung; Wu, Xiaodong; Flynn, Ryan T.

Interstitial rotating shield brachytherapy for prostate cancer Journal Article

In: Medical Physics, vol. 41, no. 5, pp. 051703, 2014, ISSN: 2473-4209.

Abstract | Links | BibTeX | Tags: Brachytherapy, Catheters, Computer-Assisted, Equipment Design, Gadolinium, Humans, Iridium Radioisotopes, Male, Monte Carlo Method, Needles, Nickel, Platinum Compounds, Prostatic Neoplasms, Radiation Protection, Radioisotopes, Radiotherapy Dosage, Radiotherapy Planning, Rectum, Time Factors, Titanium, Urethra, Urinary Bladder

@article{adams_interstitial_2014,
title = {Interstitial rotating shield brachytherapy for prostate cancer},
author = {Quentin E. Adams and Jinghzu Xu and Elizabeth K. Breitbach and Xing Li and Shirin A. Enger and William R. Rockey and Yusung Kim and Xiaodong Wu and Ryan T. Flynn},
doi = {10.1118/1.4870441},
issn = {2473-4209},
year = {2014},
date = {2014-05-01},
journal = {Medical Physics},
volume = {41},
number = {5},
pages = {051703},
abstract = {PURPOSE: To present a novel needle, catheter, and radiation source system for interstitial rotating shield brachytherapy (I-RSBT) of the prostate. I-RSBT is a promising technique for reducing urethra, rectum, and bladder dose relative to conventional interstitial high-dose-rate brachytherapy (HDR-BT).
METHODS: A wire-mounted 62 GBq(153)Gd source is proposed with an encapsulated diameter of 0.59 mm, active diameter of 0.44 mm, and active length of 10 mm. A concept model I-RSBT needle/catheter pair was constructed using concentric 50 and 75 μm thick nickel-titanium alloy (nitinol) tubes. The needle is 16-gauge (1.651 mm) in outer diameter and the catheter contains a 535 μm thick platinum shield. I-RSBT and conventional HDR-BT treatment plans for a prostate cancer patient were generated based on Monte Carlo dose calculations. In order to minimize urethral dose, urethral dose gradient volumes within 0-5 mm of the urethra surface were allowed to receive doses less than the prescribed dose of 100%.
RESULTS: The platinum shield reduced the dose rate on the shielded side of the source at 1 cm off-axis to 6.4% of the dose rate on the unshielded side. For the case considered, for the same minimum dose to the hottest 98% of the clinical target volume (D(98%)), I-RSBT reduced urethral D(0.1cc) below that of conventional HDR-BT by 29%, 33%, 38%, and 44% for urethral dose gradient volumes within 0, 1, 3, and 5 mm of the urethra surface, respectively. Percentages are expressed relative to the prescription dose of 100%. For the case considered, for the same urethral dose gradient volumes, rectum D(1cc) was reduced by 7%, 6%, 6%, and 6%, respectively, and bladder D(1cc) was reduced by 4%, 5%, 5%, and 6%, respectively. Treatment time to deliver 20 Gy with I-RSBT was 154 min with ten 62 GBq (153)Gd sources.
CONCLUSIONS: For the case considered, the proposed(153)Gd-based I-RSBT system has the potential to lower the urethral dose relative to HDR-BT by 29%-44% if the clinician allows a urethral dose gradient volume of 0-5 mm around the urethra to receive a dose below the prescription. A multisource approach is necessary in order to deliver the proposed (153)Gd-based I-RSBT technique in reasonable treatment times.},
keywords = {Brachytherapy, Catheters, Computer-Assisted, Equipment Design, Gadolinium, Humans, Iridium Radioisotopes, Male, Monte Carlo Method, Needles, Nickel, Platinum Compounds, Prostatic Neoplasms, Radiation Protection, Radioisotopes, Radiotherapy Dosage, Radiotherapy Planning, Rectum, Time Factors, Titanium, Urethra, Urinary Bladder},
pubstate = {published},
tppubtype = {article}
}

Close

PURPOSE: To present a novel needle, catheter, and radiation source system for interstitial rotating shield brachytherapy (I-RSBT) of the prostate. I-RSBT is a promising technique for reducing urethra, rectum, and bladder dose relative to conventional interstitial high-dose-rate brachytherapy (HDR-BT).
METHODS: A wire-mounted 62 GBq(153)Gd source is proposed with an encapsulated diameter of 0.59 mm, active diameter of 0.44 mm, and active length of 10 mm. A concept model I-RSBT needle/catheter pair was constructed using concentric 50 and 75 μm thick nickel-titanium alloy (nitinol) tubes. The needle is 16-gauge (1.651 mm) in outer diameter and the catheter contains a 535 μm thick platinum shield. I-RSBT and conventional HDR-BT treatment plans for a prostate cancer patient were generated based on Monte Carlo dose calculations. In order to minimize urethral dose, urethral dose gradient volumes within 0-5 mm of the urethra surface were allowed to receive doses less than the prescribed dose of 100%.
RESULTS: The platinum shield reduced the dose rate on the shielded side of the source at 1 cm off-axis to 6.4% of the dose rate on the unshielded side. For the case considered, for the same minimum dose to the hottest 98% of the clinical target volume (D(98%)), I-RSBT reduced urethral D(0.1cc) below that of conventional HDR-BT by 29%, 33%, 38%, and 44% for urethral dose gradient volumes within 0, 1, 3, and 5 mm of the urethra surface, respectively. Percentages are expressed relative to the prescription dose of 100%. For the case considered, for the same urethral dose gradient volumes, rectum D(1cc) was reduced by 7%, 6%, 6%, and 6%, respectively, and bladder D(1cc) was reduced by 4%, 5%, 5%, and 6%, respectively. Treatment time to deliver 20 Gy with I-RSBT was 154 min with ten 62 GBq (153)Gd sources.
CONCLUSIONS: For the case considered, the proposed(153)Gd-based I-RSBT system has the potential to lower the urethral dose relative to HDR-BT by 29%-44% if the clinician allows a urethral dose gradient volume of 0-5 mm around the urethra to receive a dose below the prescription. A multisource approach is necessary in order to deliver the proposed (153)Gd-based I-RSBT technique in reasonable treatment times.

Close

2013

Enger, Shirin A.; Fisher, Darrell R.; Flynn, Ryan T.

Gadolinium-153 as a brachytherapy isotope Journal Article

In: Physics in Medicine and Biology, vol. 58, no. 4, pp. 957–964, 2013, ISSN: 1361-6560.

Abstract | Links | BibTeX | Tags: Anisotropy, Brachytherapy, Equipment Design, Gadolinium, Humans, Iridium Radioisotopes, Male, Monte Carlo Method, Photons, Prostatic Neoplasms, Radiation, Radiation Protection, Radioisotopes, Radiotherapy Dosage, Scattering

@article{enger_gadolinium-153_2013,
title = {Gadolinium-153 as a brachytherapy isotope},
author = {Shirin A. Enger and Darrell R. Fisher and Ryan T. Flynn},
doi = {10.1088/0031-9155/58/4/957},
issn = {1361-6560},
year = {2013},
date = {2013-02-01},
journal = {Physics in Medicine and Biology},
volume = {58},
number = {4},
pages = {957--964},
abstract = {The purpose of this work was to present the fundamental dosimetric characteristics of a hypothetical (153)Gd brachytherapy source using the AAPM TG-43U1 dose-calculation formalism. Gadolinium-153 is an intermediate-energy isotope that emits 40-100 keV photons with a half-life of 242 days. The rationale for considering (153)Gd as a brachytherapy source is for its potential of patient specific shielding and to enable reduced personnel shielding requirements relative to (192)Ir, and as an isotope for interstitial rotating shield brachytherapy (I-RSBT). A hypothetical (153)Gd brachytherapy source with an active core of 0.84 mm diameter, 10 mm length and specific activity of 5.55 TBq of (153)Gd per gram of Gd was simulated with Geant4. The encapsulation material was stainless steel with a thickness of 0.08 mm. The radial dose function, anisotropy function and photon spectrum in water were calculated for the (153)Gd source. The simulated (153)Gd source had an activity of 242 GBq and a dose rate in water 1 cm off axis of 13.12 Gy h(-1), indicating that it would be suitable as a low-dose-rate or pulsed-dose-rate brachytherapy source. The beta particles emitted have low enough energies to be absorbed in the source encapsulation. Gadolinium-153 has an increasing radial dose function due to multiple scatter of low-energy photons. Scattered photon dose takes over with distance from the source and contributes to the majority of the absorbed dose. The anisotropy function of the (153)Gd source decreases at low polar angles, as a result of the long active core. The source is less anisotropic at polar angles away from the longitudinal axes. The anisotropy function increases with increasing distance. The (153)Gd source considered would be suitable as an intermediate-energy low-dose-rate or pulsed-dose-rate brachytherapy source. The source could provide a means for I-RSBT delivery and enable brachytherapy treatments with patient specific shielding and reduced personnel shielding requirements relative to (192)Ir.},
keywords = {Anisotropy, Brachytherapy, Equipment Design, Gadolinium, Humans, Iridium Radioisotopes, Male, Monte Carlo Method, Photons, Prostatic Neoplasms, Radiation, Radiation Protection, Radioisotopes, Radiotherapy Dosage, Scattering},
pubstate = {published},
tppubtype = {article}
}

Close

The purpose of this work was to present the fundamental dosimetric characteristics of a hypothetical (153)Gd brachytherapy source using the AAPM TG-43U1 dose-calculation formalism. Gadolinium-153 is an intermediate-energy isotope that emits 40-100 keV photons with a half-life of 242 days. The rationale for considering (153)Gd as a brachytherapy source is for its potential of patient specific shielding and to enable reduced personnel shielding requirements relative to (192)Ir, and as an isotope for interstitial rotating shield brachytherapy (I-RSBT). A hypothetical (153)Gd brachytherapy source with an active core of 0.84 mm diameter, 10 mm length and specific activity of 5.55 TBq of (153)Gd per gram of Gd was simulated with Geant4. The encapsulation material was stainless steel with a thickness of 0.08 mm. The radial dose function, anisotropy function and photon spectrum in water were calculated for the (153)Gd source. The simulated (153)Gd source had an activity of 242 GBq and a dose rate in water 1 cm off axis of 13.12 Gy h(-1), indicating that it would be suitable as a low-dose-rate or pulsed-dose-rate brachytherapy source. The beta particles emitted have low enough energies to be absorbed in the source encapsulation. Gadolinium-153 has an increasing radial dose function due to multiple scatter of low-energy photons. Scattered photon dose takes over with distance from the source and contributes to the majority of the absorbed dose. The anisotropy function of the (153)Gd source decreases at low polar angles, as a result of the long active core. The source is less anisotropic at polar angles away from the longitudinal axes. The anisotropy function increases with increasing distance. The (153)Gd source considered would be suitable as an intermediate-energy low-dose-rate or pulsed-dose-rate brachytherapy source. The source could provide a means for I-RSBT delivery and enable brachytherapy treatments with patient specific shielding and reduced personnel shielding requirements relative to (192)Ir.

Close

2006

Enger, Shirin A.; af Rosenschöld, Per Munck; Rezaei, Arash; Lundqvist, Hans

Monte Carlo calculations of thermal neutron capture in gadolinium: a comparison of GEANT4 and MCNP with measurements Journal Article

In: Medical Physics, vol. 33, no. 2, pp. 337–341, 2006, ISSN: 0094-2405.

Abstract | Links | BibTeX | Tags: Computer-Assisted, Fast Neutrons, Gadolinium, Humans, Imaging, Monte Carlo Method, Neutron Capture Therapy, Phantoms, Radiologic, Radiometry, Radiotherapy Planning, Reproducibility of Results, Technology

@article{enger_monte_2006,
title = {Monte Carlo calculations of thermal neutron capture in gadolinium: a comparison of GEANT4 and MCNP with measurements},
author = {Shirin A. Enger and Per Munck af Rosenschöld and Arash Rezaei and Hans Lundqvist},
doi = {10.1118/1.2150787},
issn = {0094-2405},
year = {2006},
date = {2006-02-01},
journal = {Medical Physics},
volume = {33},
number = {2},
pages = {337--341},
abstract = {GEANT4 is a Monte Carlo code originally implemented for high-energy physics applications and is well known for particle transport at high energies. The capacity of GEANT4 to simulate neutron transport in the thermal energy region is not equally well known. The aim of this article is to compare MCNP, a code commonly used in low energy neutron transport calculations and GEANT4 with experimental results and select the suitable code for gadolinium neutron capture applications. To account for the thermal neutron scattering from chemically bound atoms [S(alpha,beta)] in biological materials a comparison of thermal neutron fluence in tissue-like poly(methylmethacrylate) phantom is made with MCNP4B, GEANT4 6.0 patch1, and measurements from the neutron capture therapy (NCT) facility at the Studsvik, Sweden. The fluence measurements agreed with MCNP calculated results considering S(alpha,beta). The location of the thermal neutron peak calculated with MCNP without S(alpha,beta) and GEANT4 is shifted by about 0.5 cm towards a shallower depth and is 25%-30% lower in amplitude. Dose distribution from the gadolinium neutron capture reaction is then simulated by MCNP and compared with measured data. The simulations made by MCNP agree well with experimental results. As long as thermal neutron scattering from chemically bound atoms are not included in GEANT4 it is not suitable for NCT applications.},
keywords = {Computer-Assisted, Fast Neutrons, Gadolinium, Humans, Imaging, Monte Carlo Method, Neutron Capture Therapy, Phantoms, Radiologic, Radiometry, Radiotherapy Planning, Reproducibility of Results, Technology},
pubstate = {published},
tppubtype = {article}
}

Close

GEANT4 is a Monte Carlo code originally implemented for high-energy physics applications and is well known for particle transport at high energies. The capacity of GEANT4 to simulate neutron transport in the thermal energy region is not equally well known. The aim of this article is to compare MCNP, a code commonly used in low energy neutron transport calculations and GEANT4 with experimental results and select the suitable code for gadolinium neutron capture applications. To account for the thermal neutron scattering from chemically bound atoms [S(alpha,beta)] in biological materials a comparison of thermal neutron fluence in tissue-like poly(methylmethacrylate) phantom is made with MCNP4B, GEANT4 6.0 patch1, and measurements from the neutron capture therapy (NCT) facility at the Studsvik, Sweden. The fluence measurements agreed with MCNP calculated results considering S(alpha,beta). The location of the thermal neutron peak calculated with MCNP without S(alpha,beta) and GEANT4 is shifted by about 0.5 cm towards a shallower depth and is 25%-30% lower in amplitude. Dose distribution from the gadolinium neutron capture reaction is then simulated by MCNP and compared with measured data. The simulations made by MCNP agree well with experimental results. As long as thermal neutron scattering from chemically bound atoms are not included in GEANT4 it is not suitable for NCT applications.

Close

Enger, Shirin A.; Rezaei, Arash; af Rosenschöld, Per Munck; Lundqvist, Hans

Gadolinium neutron capture brachytherapy (GdNCB), a new treatment method for intravascular brachytherapy Journal Article

In: Medical Physics, vol. 33, no. 1, pp. 46–51, 2006, ISSN: 0094-2405.

Abstract | Links | BibTeX | Tags: Biological, Blood Vessel Prosthesis, Brachytherapy, Computer Simulation, Computer-Assisted, Gadolinium, Graft Occlusion, Humans, Models, Monte Carlo Method, Neutron Capture Therapy, Radiometry, Radiotherapy Dosage, Radiotherapy Planning, Relative Biological Effectiveness, Statistical, Stents, Vascular

@article{enger_gadolinium_2006,
title = {Gadolinium neutron capture brachytherapy (GdNCB), a new treatment method for intravascular brachytherapy},
author = {Shirin A. Enger and Arash Rezaei and Per Munck af Rosenschöld and Hans Lundqvist},
doi = {10.1118/1.2146050},
issn = {0094-2405},
year = {2006},
date = {2006-01-01},
journal = {Medical Physics},
volume = {33},
number = {1},
pages = {46--51},
abstract = {Restenosis is a major problem after balloon angioplasty and stent implantation. The aim of this study is to introduce gadolinium neutron capture brachytherapy (GdNCB) as a suitable modality for treatment of stenosis. The utility of GdNCB in intravascular brachytherapy (IVBT) of stent stenosis is investigated by using the GEANT4 and MCNP4B Monte Carlo radiation transport codes. To study capture rate, Kerma, absorbed dose and absorbed dose rate around a Gd-containing stent activated with neutrons, a 30 mm long, 5 mm diameter gadolinium foil is chosen. The input data is a neutron spectrum used for clinical neutron capture therapy in Studsvik, Sweden. Thermal neutron capture in gadolinium yields a spectrum of high-energy gamma photons, which due to the build-up effect gives an almost flat dose delivery pattern to the first 4 mm around the stent. The absorbed dose rate is 1.33 Gy/min, 0.25 mm from the stent surface while the dose to normal tissue is in order of 0.22 Gy/min, i.e., a factor of 6 lower. To spare normal tissue further fractionation of the dose is also possible. The capture rate is relatively high at both ends of the foil. The dose distribution from gamma and charge particle radiation at the edges and inside the stent contributes to a nonuniform dose distribution. This will lead to higher doses to the surrounding tissue and may prevent stent edge and in-stent restenosis. The position of the stent can be verified and corrected by the treatment plan prior to activation. Activation of the stent by an external neutron field can be performed days after catherization when the target cells start to proliferate and can be expected to be more radiation sensitive. Another advantage of the nonradioactive gadolinium stent is the possibility to avoid radiation hazard to personnel.},
keywords = {Biological, Blood Vessel Prosthesis, Brachytherapy, Computer Simulation, Computer-Assisted, Gadolinium, Graft Occlusion, Humans, Models, Monte Carlo Method, Neutron Capture Therapy, Radiometry, Radiotherapy Dosage, Radiotherapy Planning, Relative Biological Effectiveness, Statistical, Stents, Vascular},
pubstate = {published},
tppubtype = {article}
}

Close

Restenosis is a major problem after balloon angioplasty and stent implantation. The aim of this study is to introduce gadolinium neutron capture brachytherapy (GdNCB) as a suitable modality for treatment of stenosis. The utility of GdNCB in intravascular brachytherapy (IVBT) of stent stenosis is investigated by using the GEANT4 and MCNP4B Monte Carlo radiation transport codes. To study capture rate, Kerma, absorbed dose and absorbed dose rate around a Gd-containing stent activated with neutrons, a 30 mm long, 5 mm diameter gadolinium foil is chosen. The input data is a neutron spectrum used for clinical neutron capture therapy in Studsvik, Sweden. Thermal neutron capture in gadolinium yields a spectrum of high-energy gamma photons, which due to the build-up effect gives an almost flat dose delivery pattern to the first 4 mm around the stent. The absorbed dose rate is 1.33 Gy/min, 0.25 mm from the stent surface while the dose to normal tissue is in order of 0.22 Gy/min, i.e., a factor of 6 lower. To spare normal tissue further fractionation of the dose is also possible. The capture rate is relatively high at both ends of the foil. The dose distribution from gamma and charge particle radiation at the edges and inside the stent contributes to a nonuniform dose distribution. This will lead to higher doses to the surrounding tissue and may prevent stent edge and in-stent restenosis. The position of the stent can be verified and corrected by the treatment plan prior to activation. Activation of the stent by an external neutron field can be performed days after catherization when the target cells start to proliferate and can be expected to be more radiation sensitive. Another advantage of the nonradioactive gadolinium stent is the possibility to avoid radiation hazard to personnel.

Close

Exit mobile version